Betterment Adds $118K in Johnson & Johnson ($JNJ)
Key Points
- Betterment changed its Johnson & Johnson ($JNJ) stake by 24.0% last quarter, boosting to 2,536 shares worth $610,846.
- Wall Street's consensus rating on $JNJ is Buy and an average price target of $252.87.
- $JNJ last traded around $240.87.
Betterment increased its position in Johnson & Johnson ($JNJ) by 24.0% during the most recent quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,536 shares of Johnson & Johnson after buying 491 shares during the quarter. Betterment's holdings in Johnson & Johnson were worth $610,846 as of its most recent filing.
Johnson & Johnson ($JNJ) Stock
Johnson & Johnson Earnings
Johnson & Johnson Dividend
Analysts Set New Price Targets
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.
See Also
This instant news alert was generated by automated narrative technology and financial data from Opentrades and public regulatory filings. It is for informational purposes only and is not financial advice.